Comparison of the lossy image data compressions for the MESUR Pathfinder and for the Huygens Titan Probe

The commercial JPEG standard complies well with the specific requirements of exploratory space missions. Therefore, JPEG has been chosen to be the baseline for a series of spaceborne image data compressions (e.g. MARS94-HRSC, -WAOSS, HUYGENS-DISR, MESUR-IMP). One S/W-implementation (IMP) and one H/W-implementation (DISR) of image data compression are presented. Details of the modifications applied to standard JPEG are outlined. Finally, a performance comparison of the two implementations is given

Gonadal function in male patients after treatment for malignant lymphomas, with emphasis on chemotherapy

Gonadal function was assessed in male lymphoma survivors based on serum hormone levels (LH, FSH, testosterone, SHBG), and was related to treatment, age and observation time. Male patients ⩽50 years at diagnosis treated for Hodgkin's (HL) and/or non-Hodgkin's lymphoma (NHL) at the Norwegian Radium Hospital from 1 January 1980 to 31 December 2002 were included. Five treatment groups were defined: 1: radiotherapy only and/or low gonadotoxic chemotherapy (both HL and NHL)(‘No/low'), 2: medium gonadotoxicity chemotherapy for NHL (‘med-NHL'), 3: medium gonadotoxicity chemotherapy for HL (‘med-HL'), 4: highly gonadotoxic chemotherapy for NHL (‘high-NHL'), 5: highly gonadotoxic chemotherapy for HL (‘high-HL'). Gonadal hormone levels were categorised into three groups: 1: All gonadal hormones within normal range (normal), 2: Isolated elevated FSH, with LH, SHBG and testosterone within normal range (exocrine hypogonadism), 3: Testosterone below and/or LH above normal range (endocrine hypogonadism). One hundred and forty-four (49%) of the patients had normal gonadal hormones, 60 (20%) displayed exocrine hypogonadism and almost one-third (n=90, 30%) had endocrine hypogonadism. Compared to those treated with no/low gonadotoxic chemotherapy patients from all other treatment groups had significantly elevated risk for exocrine hypogonadism. Patients from the other treatment groups, except those in the med-NHL group, also had significantly elevated risk for endocrine hypogonadism compared with the group treated with no/low gonadotoxic chemotherapy. Men aged above 50 years at survey were about five times more likely to have endocrine hypogonadism compared with those less than 40 years. Because of the adverse health effects following long-lasting endocrine hypogonadism, gonadal hormones should be assessed regularly in male lymphoma survivors, especially after treatment with alkylating agents and high-dose chemotherapy with autologous stem cell support and in male patients who are 50 years and older

Disease- and treatment-related late sequelae in Hodgkin lymphoma

Background Given the impressive long-term remission rates in recent years, current clinical research focuses on late sequelae beyond diagnosis and treatment of Hodgkin lymphoma (HL). Objectives Following treatment of HL, early recognition and treatment of late sequelae is important. Comprehensive care should also be offered to recovering patients in the follow-up phase. Results In the long term, the general overall quality of life of HL patients and survivors is lower than in controls of the same age. The development of cancer-related fatigue (CRF), which can persist long after primary treatment, prevents long-term survivors from continuing their previous lives and returning to work. Other complications include the development of second malignant neoplasms (SMN), which represent a significant mortality risk for former patients. Organ toxicities include cardiac, pulmonary, and gonadal damage. The latter are particularly relevant for young survivors who have not yet completed family planning. Before initiating therapy, the patients should be informed about the possibility of fertility-preserving measures. Conclusion In view of persistent impairment of quality of life and the negative impact of CRF on the employment of former HL patients, models for targeted care during therapy and in the aftercare phase should urgently be further developed. Recent clinical trials in HL aim at balancing efficacy against acute and chronic sequelae